世界生物化学杂志:英文版(电子版)最新文献

{"title":"Innate immunity and wound repair: The platelet-rich fibrin advantage.","authors":"Saeed Mohammadi","doi":"10.4331/wjbc.v16.i2.107195","DOIUrl":"10.4331/wjbc.v16.i2.107195","url":null,"abstract":"<p><p>In this editorial, we comment on the article by Sá-Oliveira <i>et al</i>. We focus specifically on the role of platelet-rich fibrin (PRF) in modulating innate immunity to enhance wound repair. The process of wound healing is complex and involves a coordinated series of biological events, including inflammation, cell proliferation, and tissue remodeling. The innate immune system is important in the early stages of wound repair, with inflammation being a crucial initial phase in tissue regeneration. However, the inflammatory response should be regulated, as excessive or dysregulated inflammation can impair healing. Platelet concentrates, specifically PRF, have originated as promising tools to optimize the tissue repair process. PRF is a second-generation platelet concentrate, and the release of growth factors (GFs) plays a determining role in several aspects of wound healing, including promoting cell proliferation, stimulating angiogenesis, and modulating inflammation. PRF forms a fibrin matrix that entraps platelets and GFs. This structure allows for their sustained release over time, which is believed to provide a more favorable microenvironment for tissue repair. Recent research by Sá-Oliveira <i>et al</i> has provided valuable evidence supporting the efficacy of PRF in promoting wound healing. Their study, conducted on an animal model, demonstrated that PRF-based dressings were more effective in accelerating wound closure in the early stages of the healing process, enhancing tissue repair, and modulating the inflammatory response. We explore how PRF's unique properties contribute to a more controlled and effective healing process. By examining these findings, we aim to highlight PRF's potential as a promising therapeutic strategy for improved wound management.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"16 2","pages":"107195"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell therapy for Parkinson's disease: A new hope for neural regeneration.","authors":"Yasmin Garkani Mokhtari, Irene Varnava, Kosmas Kyrgiannis, Vasiliki Ampatsidou, Dimitrios Giakoumettis","doi":"10.4331/wjbc.v16.i2.106850","DOIUrl":"10.4331/wjbc.v16.i2.106850","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons in the substantia nigra that leads to reduced dopamine levels and impaired motor function. Current treatments only provide temporary symptom relief without addressing the underlying neuronal loss. A promising new approach for treating PD is stem cell therapy, particularly induced pluripotent stem cells and human pluripotent stem cells. They have the ability to differentiate into various neural cells, offering potential for neuronal replacement and restoration of brain function. Induced pluripotent stem cells are derived from reprogramming adult cells and present advantages such as genetic compatibility and reduced immune rejection, overcoming ethical concerns associated with embryonic stem cells. Preclinical studies show promising results, demonstrating that stem cells can differentiate into dopaminergic neurons and improve motor function in animal models. These advancements pave the way for clinical trials and potential long-term solutions for patients with PD. This review highlighted the significance of stem cell therapy in neuroregeneration and addressed preclinical successes, challenges in long-term safety, and ethical considerations, with the hope of revolutionizing PD treatment and improving patient outcomes.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"16 2","pages":"106850"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases.","authors":"Moosa Al-Hamadani, Mahmoud Darweesh, Saeed Mohammadi, Ahmed Al-Harrasi","doi":"10.4331/wjbc.v16.i2.107042","DOIUrl":"10.4331/wjbc.v16.i2.107042","url":null,"abstract":"<p><p>Chloroquine (CQ) and hydroxychloroquine (HCQ), originally developed as antimalarial drugs, have found a new purpose in treating various autoimmune diseases due to their immunomodulatory properties. These drugs work through multiple mechanisms, including inhibiting Toll-like receptor signaling, suppressing antigen presentation, and modulating autophagy. This review article provides a comprehensive analysis of the immunomodulatory effects of CQ and HCQ in several autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and others. We delve into the intricate mechanisms of action, highlighting the key immune cells involved and discussing the clinical implications of these drugs in managing autoimmune conditions. Our review covers the latest research and clinical trials, offering a comprehensive understanding of the therapeutic potential of CQ and HCQ in autoimmune diseases. We also discuss the challenges and controversies surrounding the use of these drugs, such as their long-term side effects and the need for personalized treatment approaches. By synthesizing current knowledge and identifying areas for future research, this review aims to provide a valuable resource for healthcare professionals and researchers involved in the management of autoimmune diseases.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"16 2","pages":"107042"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactivity of dressings based on platelet-rich plasma and Platelet-rich fibrin for tissue regeneration in animal model.","authors":"João Abel Sá-Oliveira, Monique Vieira Geraldo, Milena Marques, Rafael Messias Luiz, Filipe Krasinski Cestari, Ingrid Nascimento Lima, Thayná Cristine De Souza, Ana Carla Zarpelon-Schutz, Kádima Nayara Teixeira","doi":"10.4331/wjbc.v16.i1.98515","DOIUrl":"10.4331/wjbc.v16.i1.98515","url":null,"abstract":"<p><strong>Background: </strong>Skin wounds are common injuries that affect quality of life and incur high costs. A considerable portion of healthcare resources in Western countries is allocated to wound treatment, mainly using mechanical, biological, or artificial dressings. Biological and artificial dressings, such as hydrogels, are preferred for their biocompatibility. Platelet concentrates, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), stand out for accelerating tissue repair and minimizing risks of allergies and rejection. This study developed PRF and PRP-based dressings to treat skin wounds in an animal model, evaluating their functionality and efficiency in accelerating the tissue repair process.</p><p><strong>Aim: </strong>To develop wound dressings based on platelet concentrates and evaluating their efficiency in treating skin wounds in Wistar rats.</p><p><strong>Methods: </strong>Wistar rats, both male and female, were subjected to the creation of a skin wound, distributed into groups (<i>n</i> = 64/group), and treated with Carbopol (negative control); PRP + Carbopol; PRF + Carbopol; or PRF + CaCl₂ + Carbopol, on days zero (D0), D3, D7, D14, and D21. PRP and PRF were obtained only from male rats. On D3, D7, D14, and D21, the wounds were analyzed for area, contraction rate, and histopathology of the tissue repair process.</p><p><strong>Results: </strong>The PRF-based dressing was more effective in accelerating wound closure early in the tissue repair process (up to D7), while PRF + CaCl₂ seemed to delay the process, as wound closure was not complete by D21. Regarding macroscopic parameters, animals treated with PRF + CaCl₂ showed significantly more crusting (necrosis) early in the repair process (D3). In terms of histopathological parameters, the PRF group exhibited significant collagenization at the later stages of the repair process (D14 and D21). By D21, fibroblast proliferation and inflammatory infiltration were higher in the PRP group. Animals treated with PRF + CaCl₂ experienced a more pronounced inflammatory response up to D7, which diminished from D14 onwards.</p><p><strong>Conclusion: </strong>The PRF-based dressing was effective in accelerating the closure of cutaneous wounds in Wistar rats early in the process and in aiding tissue repair at the later stages.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"16 1","pages":"98515"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction.","authors":"Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi, Issa S Al-Amri","doi":"10.4331/wjbc.v16.i1.104535","DOIUrl":"10.4331/wjbc.v16.i1.104535","url":null,"abstract":"<p><p>Alcohol-associated liver disease (ALD) is a major global health concern, contributing to liver injury, morbidity, and mortality. Elafibranor (EFN), a dual peroxisome proliferator-activated receptor α/δ agonist, has shown promise as a therapeutic candidate in preclinical studies. EFN reduces liver fibrosis by inhibiting lipid accumulation, apoptosis, and inflammatory pathways (LPS/TLR4/NF-κB), while enhancing autophagy and antioxidant responses. It also improves intestinal barrier function and modulates gut microbiota, reducing endotoxin-producing bacteria and increasing beneficial species. By strengthening the intestinal barrier and suppressing pro-inflammatory mediators like tumor necrosis factor-alpha and interleukin-6, EFN mitigates hepatic stellate cell activation and fibrogenic signaling. Macrophages play a central role in ALD progression, and EFN's ability to modulate macrophage activity further highlights its anti-inflammatory properties. This review emphasizes EFN's dual-targeted approach, addressing both hepatic and intestinal dysfunctions, distinguishing it from conventional ALD treatments. While preclinical results are promising, EFN remains under clinical investigation, with ongoing trials evaluating its safety and efficacy. Future research should focus on elucidating EFN's molecular mechanisms and advancing its clinical application to establish its therapeutic potential in human populations. EFN represents a novel, comprehensive strategy for ALD management, targeting both liver and gut pathologies.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"16 1","pages":"104535"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1.","authors":"Meng-Tong Cao, You Feng, Y George Zheng","doi":"10.4331/wjbc.v14.i5.84","DOIUrl":"10.4331/wjbc.v14.i5.84","url":null,"abstract":"<p><strong>Background: </strong>Post-translational modifications play key roles in various biological processes. Protein arginine methyltransferases (PRMTs) transfer the methyl group to specific arginine residues. Both PRMT1 and PRMT6 have emerges as crucial factors in the development and progression of multiple cancer types. We posit that PRMT1 and PRMT6 might interplay directly or in-directly in multiple ways accounting for shared disease phenotypes.</p><p><strong>Aim: </strong>To investigate the mechanism of the interaction between PRMT1 and PRMT6.</p><p><strong>Methods: </strong>Gel electrophoresis autoradiography was performed to test the methyltranferase activity of PRMTs and characterize the kinetics parameters of PRMTs. Liquid chromatography-tandem mass spectrometryanalysis was performed to detect the PRMT6 methylation sites.</p><p><strong>Results: </strong>In this study we investigated the interaction between PRMT1 and PRMT6, and PRMT6 was shown to be a novel substrate of PRMT1. We identified specific arginine residues of PRMT6 that are methylated by PRMT1, with R106 being the major methylation site. Combined biochemical and cellular data showed that PRMT1 downregulates the enzymatic activity of PRMT6 in histone H3 methylation.</p><p><strong>Conclusion: </strong>PRMT6 is methylated by PRMT1 and R106 is a major methylation site induced by PRMT1. PRMT1 methylation suppresses the activity of PRMT6.</p>","PeriodicalId":57803,"journal":{"name":"世界生物化学杂志:英文版(电子版)","volume":"14 5","pages":"84-98"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}